Latest News

Fluid biomarkers: theory and practice

 

ACTRIMS Forum 2024

Considerable progress has been made in recent years in determining the place in therapy of fluid biomarkers of multiple sclerosis and other neurological disorders. Among the most studied are neurofilament-light chain (NfL), a marker of neuroaxonal damage, and glial fibrillary acidic protein (GFAP), a marker of astrogliosis. The following summarizes fluid biomarker studies presented at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum, held February 29 to March 2, 2024, in West Palm Beach, Florida. Read More